Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland-based biotech called ...
May 5, 2026 11:37 AM EDT News Briefing Second life for a gene therapy; Takeda passes Phase 2/3 test; UK cancer biotech's $83M raise ENDPOINTS A blood test might predict who will respond to Wegovy; Viridian’s thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that